Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: thymopentin - mondoBIOTECH

Drug Profile

Research programme: thymopentin - mondoBIOTECH

Alternative Names: DasKloster 0112-01; DK-0112; TP 5 - Mondobiotech; TP-5

Latest Information Update: 16 Jul 2016

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator mondoBIOTECH
  • Class Peptides
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Sarcoidosis
  • Available For Licensing Yes - Sarcoidosis

Highest Development Phases

  • No development reported Sarcoidosis
  • Discontinued Lung disorders

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for research development in Sarcoidosis in Switzerland
  • 09 Mar 2011 Research programme: thymopentin - mondoBIOTECH is available for licensing as of 09 Mar 2011. http://www.mondobiotech.com
  • 04 Feb 2011 Research programme: thymopentin - mondoBIOTECH receives Orphan Drug status for Sarcoidosis in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top